- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
NASI, Theseus announce technical milestone
North American Scientific and Theseus Imaging reported that clinical trials of Theseus’ Apomate kit have shown the agent to be effective in the noninvasive imaging of apoptosis, or cell death, associated with cardiac transplant rejection. The kit
North American Scientific and Theseus Imaging reported that clinical trials of Theseus Apomate kit have shown the agent to be effective in the noninvasive imaging of apoptosis, or cell death, associated with cardiac transplant rejection. The kit has been used in nuclear medicine procedures in more than 3500 hospitals across the U.S.
Patients who undergo heart transplants can have up to 15 catheterization procedures during the first year after the surgery to evaluate the immunosuppression medications effectiveness, according to the two companies. Theseus hopes Apomate will contribute equivalent information noninvasively by imaging the functional changes that occur when the body rejects an organ.
North American and Theseus signed a merger agreement in October, which is subject to final due diligence, according to Chatsworth, CA-based NASI. Theseus develops radiopharmaceutical products for in vivo medical imaging.
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.
FDA Clears Software for Enhancing CCTA Assessment of Atherosclerosis
October 1st 2024Through analysis of coronary computed tomography angiography (CCTA) images, the PlaqueIQ software provides quantification and classification of atherosclerosis, a common cause of myocardial infarction (MI) and ischemic stroke.
